News

Novavax, a clinical-stage biopharmaceutical company, has reported a net loss of $8.35m, or $0.12 per share, for the first quarter of 2009 compared to a net loss of

Denmark-based healthcare company Novo Nordisk has reported encouraging results from the Titrate study showing that Levemir, taken once-daily, substantially lowered average blood sugar. Approximately 60% of patients taking

PARI Pharma, a division of PARI GmbH and a developer of aerosol therapies, has received an orphan drug designation from the European Commission based on a positive recommendation

Implicit Bioscience, a biopharmaceutical company, and CMC Icos Biologics, a contract development and manufacturing organization, have signed a manufacturing contract to support the next stage of development and

Sanofi-aventis has reported the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France. The investment in this new vaccine production facility, which is located close

Results Of Operations Three months ended March 31, 2009 as compared with three months ended March 31, 2008: Operating Revenues and Expenses For the three months ended March

Recent Corporate Highlights: Achieved positive operating cash flow of $0.9 million for the second quarter of 2009 Increased Diagnostic & Biopharmaceutical Products revenue by 23% and BioServices revenue

Excluding interest, depreciation and stock-based compensation on a non-GAAP basis, the Company had net income of $203,698 for the first quarter of 2009 compared to $338,310 for the

Sales in emerging markets represented 26 % of the total of sales recorded in this quarter. Operating charges break down into sales and marketing expenses (EUR1.83 million), general